Clinical and Therapeutic Impact of Large Genomic Studies at Diagnosis in Pediatric Solid Cancers

Evaluation of the Clinical and Therapeutic Impact of Large Genomic Studies at Diagnosis in Pediatric Solid Cancers

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06171971

Acronym

CS-PEDIA

Enrollment

230

Registered

2023-12-15

Start date

2022-06-20

Completion date

2023-12-31

Last updated

2023-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pediatric Solid Tumors

Keywords

Pediatric solid tumors, BROAD GENOMIC STUDIES, SOLID CANCERS, Genomic medicine

Brief summary

Pediatric solid tumors with an unfavorable prognosis remain a public health issue due to their morbidity and mortality and their rapidly evolving profile. They are defined by an expected overall survival of \< 30%. Progress has been made in genomic medicine with existing recommendations for the adult population, with the objective of personalized medicine. Recommendations for the pediatric population are still under consideration

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

1 Years to 22 Years

Inclusion criteria

* Patients of pediatric age up to 22 years included at the time of molecular analysis * Histological carcinological diagnosis performed at HUS * Carcinological follow-up performed at HUS * Patients with a solid tumor of unfavorable prognosis, refractory or in relapse * Molecular analysis performed on tumor or blood samples * Adult patients who do not object to the re-use of their personal data for medical research purposes * Minor patients and their parents who do not object to the re-use of their personal data for scientific research purposes. Criteria for non-inclusion * Molecular biology results not usable due to poor sample quality or insufficient genetic material * Patients who have expressed their opposition to participate in the study * Parental authority holders who have expressed their opposition to participate in the study

Design outcomes

Primary

Measure	Time frame	Description
Retrospective description of the clinical and therapeutic impact of the systematic performance of molecular analyzes on solid tumors	up to 12 months	The aim of this retrospective study is to improve and harmonize international practices

Countries

France

Contacts

Primary ContactNatacha ENTZ-WERLE, MD, PhD

natacha.entz-werle@chru-strasbourg.fr33 3.88.12.87.94

Outcome results